Method of making a kink resistant stent-graft

Information

  • Patent Grant
  • 6361637
  • Patent Number
    6,361,637
  • Date Filed
    Friday, August 13, 1999
    24 years ago
  • Date Issued
    Tuesday, March 26, 2002
    22 years ago
Abstract
A stent-graft including a stent member having an inner surface and an outer surface, a generally tubular graft member and a coupling member that couples the stent member to the graft member. The coupling member, which is the preferred embodiment is in the form of a ribbon, covers only a portion of the inner or outer surface of the stent member and secures the stent member and graft member to one another. Alternatively, the coupling member can be to described as interconnecting less than entirely the inner or outer surface of the graft member to the stent member. With this construction, regions of the stent member do not interfere with the coupling member. Shear stresses between the stent member and the coupling member and the risk of tearing the graft or coupling member or delamination therebetween may be reduced as compared to a fully enveloped stent member. This construction also provides improved flexibility and kink resistance.
Description




FIELD OF THE INVENTION




This invention relates generally to implants for repairing ducts and passageways in the body. More specifically, the invention relates to an expandable stent-graft.




BACKGROUND OF THE INVENTION




Treatment or isolation of vascular aneurysms or of vessel walls which have been thinned or thickened by disease has traditionally been performed via surgical bypassing with vascular grafts. Shortcomings of this procedure include the morbidity and mortality associated with surgery, long recovery times after surgery, and the high incidence of repeat intervention needed due to limitations of the graft or of the procedure.




Vessels thickened by disease are currently sometimes treated less invasively with intraluminal stents that mechanically hold these vessels open either subsequent to or as an adjunct to a balloon angioplasty procedure. Shortcomings of current stents include the use of highly thrombogenic materials (stainless steels, tantalum, ELGILOY) which are exposed to blood, the general failure of these materials to attract and support functional endothelium, the irregular stent/vessel surface that causes unnatural blood flow patterns, and the mismatch of mechanical compliance and flexibility between the vessel and the stent.




Various attempts have been made to provide a nonthrombogenic blood-carrying conduit. Pinchuk, in U.S. Pat. Nos. 5,019,090, 5,092,887, and 5,163,958, suggests a spring stent which appears to circumferentially and helically wind about as it is finally deployed except, perhaps, at the very end link of the stent. The Pinchuk '958 patent further suggests the use of a pyrolytic carbon layer on the surface of the stent to present a porous surface of improved antithrombogenic properties.




U.S. Pat. No. 5,123,917, to Lee, suggests an expandable vascular graft having a flexible cylindrical inner tubing and a number of “scaffold members” which are expandable, ring-like and provide circumferential rigidity to the graft. The scaffold members are deployed by deforming them beyond their plastic limit using, e.g., an angioplasty balloon.




A variety of stent-graft designs also have been developed to improve upon simple stent configurations. Perhaps the most widely known stent-graft is shown in Ersek, U.S. Pat. No. 3,657,744. Ersek shows a system for deploying expandable, plastically deformable stents of metal mesh having an attached graft through the use of an expansion tool.




Palmaz describes a variety of expandable intraluminal vascular grafts in a sequence of patents: U.S. Pat. Nos. 4,733,665; 4,739,762; 4,776,337; and 5,102,417. The Palmaz '665 patent suggests grafts (which also function as stents) that are expanded using angioplasty balloons. The grafts are variously a wire mesh tube or of a plurality of thin bars fixedly secured to each other. The devices are installed, e.g., using an angioplasty balloon and consequently are not seen to be self-expanding. The Palmaz '762 and '337 patents appear to suggest the use of thin-walled, biologically inert materials on the outer periphery of the earlier-described stents. Finally, the Palmaz '417 patent describes the use of multiple stent sections each flexibly connected to its neighbor.




Rhodes, U.S. Pat No. 5,122,154, shows an expandable stent-graft made to be expanded using a balloon catheter. The stent is a sequence of ring-like members formed of links spaced apart along the graft. The graft is a sleeve of a material such as an expanded polyfluorocarbon, expanded polytetrafluoroethylene available from W. L. Gore & Associates, Inc. or IMPRA Corporation.




Schatz, U.S. Pat. No. 5,195,984, shows an expandable intraluminal stent and graft related in concept to the Palmaz patents discussed above. Schatz discusses, in addition, the use of flexibly-connecting vascular grafts which contain several of the Palmaz stent rings to allow flexibility of the overall structure in following curving body lumen.




Cragg, “Percutaneous Femoropopliteal Graft Placement”,


Radiology,


vol. 187, no. 3, pp. 643-648 (1993), shows a stent-graft of a self-expanding, nitinol, zig-zag, helically wound stent having a section of polytetrafluoroethylene tubing sewed to the interior of the stent.




Cragg (European Patent Application 0,556,850) discloses an intraluminal stent made up of a continuous helix of zig-zag wire and having loops at each apex of the zig-zags. Those loops on the adjacent apexes are individually tied together to form diamond-shaped openings among the wires. The stent may be made of a metal such as nitinol (col. 3 lines 15-25 and col. 4, lines 42+), and may be associated with a “polytetrafluoroethylene (PTFE), dacron, or any other suitable biocompatible material”. Those biocompatible materials may be inside the stent (col. 3 lines 52+) or outside the stent (col. 4, lines 6+).




WO93/13825 to Maeda et al. discloses a self-expanding stent having a wire bent into an elongated zig-zag pattern and helically would about a tubular shape interconnected with a filament. A sleeve may be attached to the outer or inner surface of the stent.




PCT application publication WO/95/05132 discloses a stent-graft with a tubular diametrically adjustable stent.




There is a need for an alternate stent-graft construction that exhibits excellent kink resistance and flexibility.




SUMMARY OF THE INVENTION




The present invention involves a stent-graft including a stent member having an inner surface and an outer surface, a generally tubular graft member and a coupling member that couples the stent member to the graft member. The coupling member, which in the preferred embodiment is in the form of a ribbon, covers only a portion of at least one of the inner or outer surface of the stent member and secures the stent member and graft member to one another. Alternatively, the coupling member can be described as interconnecting less than entirely the inner or outer surface of the stent member to the graft member.




With this construction, regions of the stent member do not interface with the coupling member. This is believed to advantageously reduce shear stresses between the stent member and the coupling member when the stent-graft undergoes bending so that tearing of the coupling and/or graft member can be minimized or eliminated. It is also believed that this arrangement minimizes the likelihood of delamination between the coupling member and the graft. If delamination were to occur, the inner portion of the stent-graft could perceivable collapse into the vessel lumen and interfere with desired blood flow. Thus, the stent-graft is believed to be capable of conforming to curves in a blood vessel lumen with minimal risk of tearing the graft or coupling member, or delamination between the stent and graft members.




According to another aspect of the invention, the coupling member is secured to the graft member without sutures. When the graft member is placed within the stent member, for example, this arrangement eliminates the need for having sutures extend into the lumen formed by the graft member and possibly interfere with blood flow. Another benefit of this arrangement, as compared to suturing the stent to the graft member, is that suture holes need not be placed in the graft which could adversely affect its integrity. The coupling member may be thermally or adhesively bonded to the graft member.




The coupling member preferably has a generally broad or flat working surface as compared to filament or thread-like structures such as sutures. As noted above, a preferred coupling member is in the form of a ribbon. This configuration advantageously increases potential bonding surface area between the coupling member and the graft member to enhance the integrity of the bond therebetween. The increased bonding surface may facilitate minimizing the thickness of the coupling member so that the stent-graft lumen volume and blood flow dynamics therein can be optimized. For example, a thicker coupling member would increase the overall stent-graft thickness which can cause an undesirable lumen diameter reduction at the transition where the vessel lumen interfaces the inlet of the stent-graft. This, in turn, can result in undesirable turbulent flow which possibly can lead to complications such as thrombosis.




According to a preferred embodiment of the invention, the coupling member is arranged in a helical configuration with multiple turns. Each of a number of the coupling member turns is spaced from the turn(s) adjacent thereto. With this construction, a generally uniform distribution of coupling member-free stress relief zones may be achieved. Elastic wrinkling in the graft member may occur in those zones so that the graft member can absorb stress when bent along its longitudinal axis, for example, and resist kinking.




According to a preferred stent member construction for use with the stent-graft of the present invention, at least a portion of the stent member includes undulations and is arranged in a helical configuration with multiple turns. Each stent member undulation includes an apex and an open base portion. The apexes and base portions are configured so as not to restrain one apex into the undulation in an adjacent turn and substantially in-phase therewith when the stent-graft is bent or compressed. This is believed to facilitate undulation movement during bending or compression and minimize the likelihood of stress build-up that may cause kinking. The coupling member typically covers a substantial portion of each undulation so as to minimize the likelihood of the stent member apexes bending away from the graft member and interfering with the environment or tether line which may be used to maintain the stent-graft in a folded state before deployment. The coupling member also may be positioned adjacent to the apexes to minimize the likelihood of such apex movement.




According to another aspect of the invention, the end portions of the stent-member also may be enveloped between the coupling member or discrete coupling members and the graft member. This prevents the terminal portions of the stent and graft members from significantly moving away from one another. For example, when the stent-member is external to the graft member, the terminal graft portions may flap away from the stent member and possibly interfere with blood flow if the terminal coupling portions were not present.




According to another feature of the invention, the stent-graft is advantageously manufactured by placing a cushioning layer around a mandrel, assembling the stent-graft on the cushioning layer, surrounding the mandrel mounted assembly with a multi-component member formed from a PTFE tube having a longitudinal slit and which is wrapped with an expanded PTFE or other film or tape to compress the assembly, and heating the assembly to bond a coupling member to the graft.




The above is a brief description of some deficiencies in the prior art, and advantages and aspects of the present invention. Other features, advantages, and embodiments of the invention will be apparent to those skilled in the art from the following description, accompanying drawings and appended claims.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1A

is a perspective view of a stent-graft constructed in accordance with the principles of the present: invention.





FIG. 1B

is an enlarged perspective view of a mid-portion of the stent-graft shown in FIG.


1


A.





FIG. 1C

is an enlarged perspective view of a portion of the stent-graft shown in

FIG. 1A

mounted on a cushioned mandrel.





FIG. 2

is a side view of an enlarged portion of the stent-graft shown in FIG.


1


A.





FIG. 3A

is a diagrammatic representation of a transverse section of the stent-graft of

FIG. 1

prior to the coupling and graft members being secured to one another.





FIG. 3B

is an enlarged portion of the section shown in

FIG. 3A

after the coupling and graft members have been secured to one another.





FIG. 4

illustrates the stent-graft of

FIGS. 1A & 1B

under longitudinal, axial compression.





FIG. 5

is a sectional view of the stent-graft of

FIGS. 1A and 1B

taken along line


5





5


in FIG.


4


.





FIG. 6

diagrammatically shows a portion of the stent-graft of

FIGS. 1A and 1B

bent along its longitudinal axis.





FIG. 7

is a perspective view of another embodiment of the stent-graft of the present invention having an alternate stent to graft coupling configuration.





FIG. 8

is a side view of an enlarged portion of the stent-graft shown in FIG.


7


.





FIG. 9

is a perspective view of a further embodiment of the stent-graft of the present invention having yet another stent to graft coupling.





FIG. 10

is a side view of an enlarged portion of the stent-graft shown in FIG.


9


.





FIG. 11

is a partial view of the stent-graft of

FIG. 1A

showing an end portion of the device.





FIG. 12

is an abstracted portion of a suitable stent and shows the concept of torsion on a portion of that stent.





FIG. 13A

diagrammatically shows a further stent-member of the present invention with flared ends (the coupling tape drawn back to more clearly show the helically wound undulating stent configuration).





FIG. 13B

diagrammatically shows a further stent-member construction for supporting the graft member.





FIGS. 14A

,


14


B,


14


C,


14


D,


14


E, and


14


F are plan views of unrolled stent forms suitable for use in the invention.





FIGS. 15A

,


15


C and


15


E show procedures for folding the stent-grafts.

FIGS. 15B

,


15


D, and


15


F show the corresponding folded stent-grafts.





FIGS. 16A

,


16


B, and


16


C diagrammatically show a procedure for deploying the stent-grafts using an external sleeve.





FIGS. 17A and 18A

are partial perspective views of folded stent-grafts.

FIGS. 17B

,


18


C,


18


B, and


18


C are end views of the stent-grafts shown in

FIGS. 17A and 18A

in folded and open states.





FIGS. 19A

,


19


B, and


19


C diagrammatically show a procedure for deploying the stent-grafts shown in

FIGS. 17A-17C

and


18


A-


18


C using a tether wire.





FIG. 20

show a close-up view of a stent fold line using a preferred sack knot in the slip line.





FIG. 21

is a diagrammatic perspective view of a folded stent-graft held in a position by a tether line and a sack knot as illustrated in FIG.


20


.





FIGS. 22

,


23


,


24


, and


25


are diagrammatic sequential illustrations of a further deployment procedure.











DESCRIPTION OF THE PREFERRED EMBODIMENTS




Referring to the drawings in detail wherein like numbers indicate like elements, an expandable stent-graft


2


is shown constructed according to the principles of the present invention. Although particular stent and graft constructions will be described in conjunction with the preferred embodiments, it should be understood that other constructions may be used without departing from the scope of the invention.




Referring to

FIGS. 1A and B

, stent-graft


2


generally includes a thin-walled tube or graft member


4


, a stent member


6


and a coupling member


8


for coupling the stent and graft members together. Preferably, the stent and graft members are coupled together so that they are generally coaxial.




Tubular expandable stent member


6


is generally cylindrical and comprises a helically arranged undulating member


10


having plurality of helical turns


12


and preferably comprising nitinol wire. The undulations preferably are aligned so that they are “in-phase” with each other as shown in

FIGS. 1A and 1B

, for example. More specifically, undulating helical member


10


forms a plurality of undulations


14


, each including an apex portion


16


and a base portion


18


. When the undulations are in-phase, apex portions


16


in adjacent helical turns


12


are aligned so that an apex portion


16


may be displaced into a respective base portion


18


of a corresponding undulation in-phase therewith and in an adjacent helical turn.




Once the undulations are aligned so that adjacent undulations in one turn are in-phase with the undulations in the helical turns adjacent thereto, a linking member


20


may be provided to maintain the phased relationship of the undulations during compression and deployment, and during bending of the stent member. In the illustrative embodiment, linking member


20


is laced or interwoven between undulations in adjacent turns of the helical member and acquires a helical configuration (See, e.g., FIGS.


1


-


3


). Linking member


20


preferably comprises a biocompatible polymeric or metallic material having sufficient flexibility to be readily folded upon itself.




Undulations


14


preferably are unconfined in that they are configured so as not to tend to inhibit the movement of flexible link


20


down between respective torsion arms or lengths


22




a


and


22




b.


In addition, the undulations preferably are configured and arranged so that a respective apex portion can readily move within a corresponding undulation base portion


18


in-phase therewith. It is believed that this construction minimizes the likelihood of stress build-up, for example, during bending or compression (as depicted in the lower portion of

FIG. 6

) and, thus, improves the kink resistance of the stent-graft.




Referring to

FIGS. 3A and 3B

, stent member


6


is disposed between generally tubular graft member


4


and coupling member


8


. The stent member provides a support structure for the graft member to minimize the likelihood of the graft member collapsing during use. Although the graft member may surround the outer surface of the stent member, it preferably is placed within the stent member to provide a relatively smooth (wrinkles may form in the graft member between coupling member turns during compression) intralumental stent-graft surface as shown in the drawings.




An important aspect of the invention is that the coupling member, which secures the stent member to the graft member, covers only a portion of the stent member. Alternatively, the coupling member can be described as is preferably interconnecting less than entirely the inner or outer surface of the stent member to the graft member (e.g., it covers less than all of the outer surface of the stent member when the graft member is positioned inside the stent member). With this construction, regions of the stent member do not interface with the coupling member when the stent-graft is an uncompressed state, for example. This is believed to advantageously reduce shear stresses between the stent member and the coupling member when the stent-graft undergoes bending or compression, thereby reducing the risk of tearing the graft or coupling member or causing delamination between the stent and graft members.




The coupling member also preferably has a generally broad or flat surface for interfacing with the stent and graft members as compared to filament or thread-like structures such as sutures. This increases potential bonding surface area between the coupling member and the graft member to enhance the structural integrity of the stent-graph. The increased bonding surface area also facilitates minimizing the thickness of the coupling member. It has been found that a coupling member in a form of a generally flat ribbon or tape as shown in the drawings and designated with reference numeral


8


, provides the desired results.




As noted above, coupling member


8


preferably is in the form of a generally flat ribbon or tape having at least one generally flat surface. In addition, coupling member


8


is arranged in a helical configuration according to the preferred embodiments illustrated in the drawings. Referring to

FIG. 2

, helically arranged coupling member


8


is formed with multiple helical turns


23


, each being spaced from the turns adjacent thereto, thereby forming coupling member-free stress relief zones


24


between adjacent turns. The coupling member also preferably is arranged to provide a generally uniform distribution of stress relief zones


24


. In the illustrated embodiments, coupling member


8


is helically wound around the stent member with its helical turns


23


aligned with the stent member turns


12


. As shown, the coupling member may be constructed with a constant width and arranged with uniform spacing between turns.




Coupling member


8


also preferably covers a substantial portion of each undulation so as to minimize the likelihood of the stent member apexes lifting away from the graft member and interfering with their immediate environment. Coupling members having widths of 0.025, 0.050 and 0.075 inches have been applied to the illustrated stent member having a peak-to-peak undulation amplitude of about 0.075 inch with suitable results. However, it has been found that as the coupling member band width increases, the stent-graft flexibility generally is diminished. It is believed that coupling member width of about one-forth to three-fourths the amplitude of undulations


14


, measured peak-to-peak, is preferred (more preferably about one third to two thirds that amplitude) to optimize flexibility. It also has been found that by positioning one of lateral margins of the ribbon-shaped coupling member


8


adjacent to the apexes, e.g., in abutment with linking member


20


, the coupling member width may be reduced without significantly sacrificing apex securement. Varying the width of the coupling member can also result in the adjustment of other structural properties. Increasing the width can also potentially increase the radial stiffness and the burst pressure and decrease the porosity of the device. Increasing band width can also diminish graft member wrinkling between coupling member turns.




Coupling member


8


(or separate pieces thereof) also surrounds the terminal end portions of the stent-graft to secure the terminal portions of the graft member to the support structure formed by stent member


6


as shown in

FIG. 11

, for example.




Although the coupling member may cover a substantial portion of each undulation as discussed above, apex portions


16


may still move within the undulations in-phase therewith as shown in

FIGS. 4-6

due primarily to the flexibility of coupling and linking members


8


and


20


respectively. Further, coupling member


8


may be wrapped so as to be completely external to stent member


6


as shown in

FIGS. 1-6

, interwoven above and below alternating undulations


14


as shown in

FIGS. 7 and 8

, or interwoven above and below alternating undulation arms


22




a


and


22




b


as shown in

FIGS. 9 and 10

. In addition, the ribbon-shaped tape or coupling member


8


may be axially spaced away from the apexes and linking member


20


(

FIGS. 9 and 10

) as compared to the embodiments shown in

FIGS. 1-8

. This spacing provides an area


28


in which linking member


20


can freely move without restraint, thereby reducing any resistance placed on apexes moving into corresponding undulations during compression or bending.




The coupling member


8


may be wrapped (placed) on or interwoven with the undulations of the stent before or after it is positioned around the graft. For example the coupling member may be placed on or interwoven with the undulations of element


10


of FIG.


14


A. As a result of fluorinated ethylene propylene (FEP) coating on a surface of the coupling member, element


10


will be bonded to the coupling member by heating. The resulting element is then configured into the stent of this invention. Placing or wrapping the coupling member is performed in a manner similar to that described and shown for

FIGS. 1-11

.




Although a particular coupling member configuration and pattern has been illustrated and described, other configuration and/or patterns may be used without departing from the scope of the present invention. For example, coupling member(s) arranged in a multiple helix (e.g., a double or triple helix) may be used. Longitudinally extending strips of ribbon may be used and may be preferred when the coupling member is used in conjunction with other stent member configurations.




Each undulation


14


alternatively may be described as a torsion segment and for purposes of the following discussion will be referred to as a torsion segment


14


. Referring to

FIG. 12

, an isolated undulation


14


is shown to facilitate the following discussion involving stent mechanics involved in deployment of the device. Each torsion segment includes an apex portion


16


and two adjacent torsion arms or lengths


22




a


and


22




b


extending therefrom. Typically, then, each torsion arm


22




a


&


b


will be a component of each of two adjacent torsion segments


14


. When torsion segment


14


undergoes a flexing in the amount of α apex portion


16


will flex some amount β°, torsion arm


22




a


will undertake a twist of γ° and torsion arm


22




b


will undertake a twist opposite of that found in torsion arm


22




a


in the amount of δ°. The amounts of angular torsion found in the torsion arms (


22




a


&


22




b


) will not necessarily be equal because the torsion arms will not necessarily be equal because the torsion arms are not necessarily at the same angle to the longitudinal axis of the stent-member. Nevertheless, the sum of β°+γ°+δ° will equal α°. When a value of α° is chosen, as by selection of the shape and size of the stent-member upon folding, the values of the other three angles (β°, γ°, δ°) are chosen by virtue of selection of number or torsion segments around the stent, size and physical characteristics of the wire, and length of the torsion areas (


22




a


&


b


). Each of the noted angles must not be so large as to exceed the values at which the chosen material of construction plastically deforms at the chosen value of α°.




To further explain: it should be understood that torsion segment


14


undergoes a significant amount of flexing as the stent-member is folded or compressed in some fashion. The flexing provides a twist to the torsion arms (


22




a


&


b


), a significant portion of which is generally parallel to the longitudinal axis of the stent.




The described stent-member uses concepts which can be thought of as widely distributing and storing the force necessary to fold the tubular stent into a configuration which will fit through a diameter smaller than its relaxed outside diameter without inducing plastic deformation of the constituent metal or plastic and yet allowing those distributed forces to expand the stent upon deployment.




Once the concept of distributing the folding or compression stresses both into a bending component ( as typified by angle β° in

FIG. 12

) and to twisting components ( as typified by angle γ° and δ° in

FIG. 12

) and determining the overall size of a desired stent, determination of the optimum materials as well as the sizes of the various integral components making up the stent becomes straightforward. Specifically, the diameter and length of torsion lengths, apex portion dimensions and the number of torsion segments around the stent may then be determined.




Referring to

FIG. 13A

, a stent-graft


iv


differing from stent-graft


1


in graft support structure is shown. Stent-graft


2




iv


includes stent member


6


′ which is the same as stent member


6


with the exception that it includes flared end portions


142


at one or both ends. Flared end portions


142


provide secure anchoring of the resulting stent-graft


2




iv


against the vessel wall and prevents the implant from migrating downstream. In addition, flared end portions


142


provide a tight seal against the vessel so that the blood is channeled through the lumen rather than outside the graft. The undulating structure may vary in spacing to allow the helical turns to maintain their phased relationship as discussed above. Although a linking member between the continuous helical turns is not shown, such structure preferably is included to maintain the alignment of the apexes as discussed above.




The graft support structure also may be made by forming a desired structural pattern out of a flat sheet. The sheet may then be rolled to form a tube. The stent also may be machined from tubing. If the chosen material is nitinol, careful control of temperature during the machining step may be had by EDM (electro-discharge-machining), laser cutting, chemical machining, or high pressure water cutting. As shown in

FIG. 13B

, the stent-member (graft support structure) may comprise multiple tubular members or sections


50


, each coupled to the graft-member


4


with a coupling member as described above. Tubular members or sections


50


may have various construction and, thus, may be configured to have the same construction as the stent-member


6


shown in

FIGS. 1-11

, for example. Tubular members also may be directly coupled to each other (e.g., with bridging element(s) extend between adjacent sections as would be apparent to one of ordinary skill) or, indirectly coupled to each other through their interconnection with the graft member.




Referring to

FIGS. 14A-F

, various undulation configurations suitable for the present invention are shown.

FIG. 14A

shows the sinusoidal shaped undulating member


10


described above. Adjacent torsion arms


22




a


&


b


are not parallel.

FIG. 14B

shows an undulating member


10


′ having generally U-shaped undulations or torsion members where the torsion arms are generally parallel.

FIG. 14C

shows a further variation where undulating member


10


″ includes ovoid shaped undulations or torsion segments. In this variation, adjacent torsion arms


22





a


&


b


are again not parallel, but generally form an open-ended oval.

FIG. 14D

shows another variation where undulating member


10


′″ includes V-shaped torsion members. In this variation, the adjacent torsion arms


120


form a relatively sharp angle at the respective apex portions.

FIG. 14E

shown undulating member


10




iv


in which adjacent undulations have different amplitudes. The peaks of the large amplitude torsion segments


119


may be lined up “out of phase” or “peak to peak” with small or large amplitude torsion segments


110


,


121


, respectively, in the adjacent turn of the helix or may be positioned “in phase” similar to those discussed with regard to

FIGS. 1A and B

above. The configurations shown in

FIGS. 14A-14E

are exceptionally kink-resistant and flexible when flexed along the longitudinal axis of the stent-member.

FIG. 14F

shows a stent formed from sections


11


and


13


which are connected to one another by sutures


15


.




As discussed above, the stent member preferably is oriented coaxially with the tubular graft member. Although the stent member may be placed within the graft member, it preferably is placed on the outer surface of the graft member so that a relatively smooth graft wall interfaces with the blood. In certain configurations, an additional graft member may be placed on the outer surface of the stent-graft illustrated in the drawings. When the multiple graft structure is utilized, the stent structure should have the strength and flexibility to urge the graft tubing firmly against the vessel wall so that the graft member conforms with the inner surface of the vessel wall. In addition, the graft member preferably is impermeable to blood at normal or physiologic blood pressures. The impermeability makes the stent-graft suitable for shunting and thereby hydraulically isolating aneurysms.




The scope of materials suitable for the stent and graft members and the linking member as well as deployment mechanisms will be discussed in detail, below.




Stent Materials




The stent member is constructed of a reasonably high strength material, i.e., one which is resistant to plastic deformation when stressed. Preferably, the stent member comprises a wire which is helically wound around a mandrel having pins arranged thereon so that the helical turns and undulations can be formed simultaneously. Other constructions also may be used. For example, an appropriate shape may be formed from a flat stock and wound into a cylinder or a length of tubing formed into an appropriate shape.




In order to minimize the wall thickness of the stent-graft, the stent material should have a high strength-to-volume ratio. Use of designs as depicted herein provides stents which may be longer in length than conventional designs. Additionally, the designs do not suffer from a tendency to twist (or helically unwind) or to shorten as the stent-graft is deployed. As will be discussed below, materials suitable in these stents and meeting these criteria include various metals and some polymers.




A percutaneously delivered stent-graft must expand from a reduced diameter, necessary for delivery, to a larger deployed diameter. The diameters of these devices obviously vary with the size of the body lumen into which they are placed. For instance, the stents of this invention may range in size from 2.0 mm in diameter (for neurological applications) to 40 mm in diameter (for placement in the aorta). A range of about 2.0 mm to 6.5 mm (perhaps to 10.0 mm) is believed to be desirable. Typically, expansion ratios of 2:1 or more are required. These stents are capable of expansion ratios of up to 5:1 for larger diameter stents. Typical expansion ratios for use with the stents-grafts of the invention typically are in the range of about 2:1 to about 4:1 although the invention is not so limited. The thickness of the stent materials obviously varies with the size (or diameter) of the stent and the ultimate required yield strength of the folded stent. These values are further dependent upon the selected materials of construction. Wire used in these variations are typically of stronger alloys, e.g., nitinol and stronger spring stainless steels, and have diameters of about 0.002 inches to 0.005 inches. For the larger stents, the appropriate diameter for the stent wire may be somewhat larger, e.g., 0.005 to 0.020 inches. For flat stock metallic stents, thickness of about 0.002 inches to 0.005 inches is usually sufficient. For the larger stents, the appropriate thickness for the stent flat stock may be somewhat thicker, e.g., 0.005 to 0.020 inches.




The stent-graft is fabricated in the expanded configuration. In order to reduce its diameter for delivery the stent-graft would be folded along its length, similar to the way in which a PCTA balloon would be folded. It is desirable, when using super-elastic alloys which also have temperature-memory characteristics, to reduce the diameter of the stent at a temperature below the transition-temperature of the alloys. Often the phase of the alloy at the lower temperature is somewhat more workable and easily formed. The temperature of deployment is desirably above the transition temperature to allow use of the super-elastic properties of the alloy.




There are a variety of disclosures in which super-elastic alloys such as a nitinol are used in stents. See, U.S. Pat. Nos. 4,503,569 to Dotter, 4,512,338 to Balko et al., 4,990,155 to Wilkoff, 5,037,427 to Harada, et al., 5,147,370 to MacNamara et al., 5,211,658 to Clouse, and 5,221,261 to Termin et al. None of these references suggest a device having discrete individual, energy-storing torsional members.




Jervis, in U.S. Pat. Nos. 4,665,906 and 5,067,957, describes the use of shape memory alloys having stress-induced martensite properties in medical devices which are implantable or, at least, introduced into the human body.




It should be clear that a variety of materials variously metallic, superelastic alloys, and preferably nitinol, are suitable for use in these stents. Primary requirements of the materials are that they be suitably springy even when fashioned into very thin sheets or small diameter wires. Various stainless steels which have been physically, chemically, and otherwise treated to produce high springiness are suitable, as are other metal alloys such as cobalt chrome alloys (e.g., ELGILOY), platinum/tungsten alloys, and especially the nickel-titanium alloys generically known as “nitinol”.




Nitinol is especially preferred because of its “super-elastic” or “pseudo-elastic” shape recovery properties, i.e., the ability to withstand a significant amount of bending and flexing and yet return to its original form without deformation. These metals are characterized by their ability to be transformed from an austenitic crystal structure to a stress-induced martensitic structure at certain temperatures, and to return elastically to the austenitic shape when the stress is released. These alternating crystalline structures provide the alloy with its super-elastic properties. These alloys are well known but are described in U.S. Pat. Nos. 3,174,851, 3,351,463, and 3,753,700. Typically nitinol will be nominally 50.6% (±0.2%) Ni with remainder Ti. Commercially available nitinol materials usually will be sequentially mixed, cast, formed, and separately cold-worked to 30-40%, annealed, and stretched. Nominal, ultimate yield strength values for commercial nitinol are in the range of 30 psi and for Young's modulus are about 700 Kbar.




The '700 patent describes an alloy containing a higher iron content and consequently has a higher modulus than the Ni—Ti alloys.




Nitinol is further suitable because it has a relatively high strength to volume ratio. This allows the torsion members to be shorter than for less elastic metals. The flexibility of the stent-graft is largely dictated by the length of the torsion segments and/or torsion arms. The shorter the pitch of the device, the more flexible the stent-graft structure can be made. Materials other than nitinol are suitable. Spring tempered stainless steels and cobalt-chromium alloys such as ELGILOY are also suitable as are a wide variety of other known “super-elastic” alloys.




Although nitinol is preferred in this service because of its physical properties and its significant history in implantable medical devices, we also consider it also to be useful in a stent because of its overall suitability with magnetic resonance imaging (MRI) technology. Many other alloys, particularly those based on iron, are an anathema to the practice of MRI causing exceptionally poor images in the region of the alloy implant. Nitinol does not cause such problems.




Other materials suitable as the stent include certain polymeric materials, particularly engineering plastics such as thermotropic liquid crystal polymers (“LCP's”). These polymers are high molecular weight materials which can exist in a so-called “liquid crystalline state” where the material has some of the properties of a liquid (in that it can flow) but retains the long range molecular order of a crystal. There term “thermotropic” refers to the class of LCP's which are formed by temperature adjustment. LCP's may be prepared from monomers such as p,p′-dihydroxy-polynuclear-aromatics or dicarboxy-polynuclear-aromatics. The LCP's are easily formed and retain the necessary interpolymer attraction at room temperature to act as high strength plastic artifacts as are needed as a foldable stent. They are particularly suitable when augmented or filled with fibers such as those of the metals or alloys discussed below. It is to be noted that the fibers need not be linear but may have some preforming such as corrugations which add to the physical torsion enhancing abilities of the composite.




Linking Member Materials




Flexible link


20


, which is slidably disposed between adjacent turns of the helix may be of any appropriate filamentary material which is blood compatible or biocompatible and sufficiently flexible to allow the stent to flex and not deform the stent upon folding. Although the linkage may be a single or multiple strand wire (platinum, platinum/tungsten, gold, palladium, tantalum, stainless steel, etc.), much preferred in this invention is the use of polymeric biocompatible filaments. Synthetic polymers such as polyethylene, polypropylene, polyurethane, polyglycolic acid, polyesters, polyamides, their mixtures, blends and copolymers are suitable; preferred of this class are polyesters such as, polyethylene terephthalate including DACRON and MYLAR and polyaramids such as KEVLAR, polyfluorocarbons such as polytetrafluoroethylene with and without copolymerized hexafluoropropylene, TEFLON or ePTFE, and porous or nonporous polyurethanes. Natural materials or materials based on natural sources such as collagen may also be used in this service.




Graft Member Materials




The tubular component or graft member of the stent-graft may be made up of any material which is suitable for use as a graft in the chosen body lumen. Many graft materials are known, particularly known are those used as vascular graft materials. For instance, natural materials such as collagen may be introduced onto the inner surface of the stent and fastened into place. Desirable collagen-based materials include those described in U.S. Pat. No. 5,162,430, to Rhee et al, and WO 94/01483 (PCT/US93/06292), the entirety of which are incorporated by reference. Synthetic polymers such as polyethylene, polypropylene, polyurethane, polyglycolic acid, polyesters, polyamides, their mixture, blends, copolymers, mixtures, blends and copolymers are suitable, preferred of this class are polyesters such as polyethylene terephthalate including DACRON and MYLAR and polyaramids such as KEVLAR, polyfluorocarbons such as polytetrafluoroethylene (PTFE) with and without copolymerized hexafluoropropylene, expanded or not-expanded PTFE, and porous or nonporous polyurethanes. Especially preferred in this invention are the expanded fluorocarbon polymers (especially PTFE) materials described in British Pat. Nos. 1,355,373, 1,506,432, or 1,506,432 or in U.S. Pat. Nos. 3,953,566, 4,187,390, or 5,276,276, the entirety of which are incorporated by reference.




Included in the class of preferred fluoropolymers are polytetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), copolymers of tetrafluorethylene (TFE), and perfluoro (propyl vinyl ether) (PFA), homopolymers of polychlorotrifluoroethylene (PCTFE), and its copolymers with TFE, ethylene-chlorotrifluoroethylene (ECTFE), copolymers of ethylene-tetrafluoroethylene (ETFE), polyvinylidene fluoride (PVDF), and polyvinyfluoride (PVF). Especially preferred, because of its widespread use in vascular protheses, is expanded PTFE.




In addition, one or more radio-opaque metallic fibers, such as gold, platinum, platinum-tungsten, palladium, platinum-iridium, rhodium, tantalum, or alloys or composites of these metals like may be incorporated into the device, particularly, into the graft, to allow fluoroscopic visualization of the device.




The tubular component may also be reinforced using a network of small diameter fibers. The fibers may be random, braided, knitted or woven. The fibers may be imbedded in the tubular component, may be placed in a separate layer coaxial with the tubular component, or may be used in a combination of the two.




A preferred material for the graft and coupling members is porous expanded polytetrafluorethylene. An FEP coating is one preferred adhesive that is provided on one side of the coupling member.




Manufacture of the Stent-Graft




The following example is provided for purposes of illustrating a preferred method of manufacturing a stent-graft constructed according to the present invention which in this example case is the stent-graft shown in

FIGS. 1-6

. It should be noted, however, that this example is not intended to limit the invention.




The stent member wire is helically wound around a mandrel having pins positioned thereon so that the helical structure and undulations can be formed simultaneously. While still on the mandrel, the stent member is heated to about 460° F. for about 20 minutes so that it retains its shape.




Wire sizes and materials may vary widely depending on the application. The following is an example construction for a stent-graft designed to accommodate 6 mm diameter vessel lumen. The stent member comprises a nitinol wire (50.8 atomic % Ni) having a diameter of about 0.007 inch. In this example case, the wire is formed to have sinusoidal undulations, each having an amplitude measured peak-to-peak of about 0.100 inch and the helix is formed with a pitch of about 10 windings per inch. The inner diameter of the helix (when unconstrained) is about 6.8 mm. The nitinol wire may be polished if desired. If a polished wire is desired, the wire is fed through an electrolytic bath having an applied potential to electrolytically clean, passivate and polish the wire. The polishing reduces the availability of surface nickel for extraction or corrosion. Suitable electrolytic treating materials for the bath are commercially available. One such source of a commercially available electrolytic treating material is NDC (Nitinol Devices and Components. The linking member can be arranged as shown in the drawings and may have a diameter of about 0.006 inch.




In this example, the graft member is porous expanded polytetrafluorethylene (PTFE), while the coupling member is expanded PTFE coated with FEP. The coupling member is in the form of a flat ribbon (as shown in the illustrative embodiments) that is positioned around the stent and graft members as shown in

FIGS. 1-3

. The side of the coupling member or ribbon that is FEP coated faces the graft member to secure it to the graft member. The intermediate stent-graft construction is heated to allow the materials of the ribbon and graft member to merge and self-bind as will be described in more detail below.




The FEP-coated porous expanded PTFE film used to form the ribbon shaped coupling member preferably is made by a process which comprises the steps of:




(a) contacting a porous PTFE film with another layer which is preferably a film of FEP or alternatively of another thermoplastic polymer.




(b) heating the composition obtained in step (a) to a temperature above the melting point of the thermoplastic polymer;




(c) stretching the heated composition of step (b) while maintaining the temperature above the melting point of the thermoplastic polymer, and




(d) cooling the product of step (c)




In addition to FEP, other thermoplastic polymers including thermoplastic fluoropolymers may also be used to make this coated film. The adhesive coating on the porous expanded PTFE film may be either continuous (non-porous) or discontinuous (porous) depending primarily on the amount and rate of stretching, the temperature during stretching, and the thickness of the adhesive prior to stretching.




The thin wall expanded PTFE graft used to construct this example contains an inner tube of PTFE and an outer helical wrap of PTFE. The graft was about 0.1 mm (0.004 in) thickness and had a density of about 0.5 g/cc. The microstructure of the porous expanded PTFE contained fibrils of about 25 micron length. A 3 cm length of this graft material was placed on a mandrel the same diameter as the inner diameter of the graft. Advantageously, as shown in

FIG. 1C

, a cushioning layer


5


was placed on the mandrel


3


prior to placement of the graft


4


. The nitinol stent member having about a 3 cm length was then carefully fitted over the center of the thin wall graft


4


and extended to its desired length. Any struts out of phase should be placed in phase prior to applying the coupling member.




The stent-member was then provided with a ribbon shaped coupling member comprised of the FEP coated film as described above. The coupling member was helically wrapped around the exterior surface of the stent-member as shown in

FIGS. 1-6

. The uniaxially-oriented fibrils of the microstructure of the helically-wrapped ribbon were helically-oriented about the exterior of stent surface. The ribbon shaped coupling member was oriented so that its FEP-coated side faced inward and contacted the exterior of surface of the stent-member. This ribbon surface was exposed to the outward facing surface of the thin wall graft member exposed through the openings in the stent member.




Advantageously, an outer, multi-component sheath


9


, formed by a longitudinally slit tube of non-adhering PTFE and an outer helical wrap of non-adhering PTFE is placed around the stent-graft-coupling member assembly to compress the assembly onto the mandrel (FIG.


1


C). Alternatively, sheath


9


may be formed by helically wrapping PTFE around the stent-graft-coupling assembly without the longitudinally slit tube.




The mandrel assembly was placed into an oven set at 315° C. for a period of 15 minutes after which the film-wrapped mandrel was removed from the oven and allowed to cool. Following cooling to approximately ambient temperature, the mandrel, as well as the cushioning layer and outer compression tube, was removed from the resultant stent-graft. The amount of heat applied was adequate to melt the FEP-coating on the porous expanded PTFE film and thereby cause the graft and coupling members to adhere to each other. Thus, the graft member was adhesively bonded to the inner surface of helically-wrapped coupling member


8


through the openings between the adjacent wires of the stent member. The combined thickness of the luminal and exterior coverings (graft and coupling members) and the stent member was about 0.4 mm.




The stent-graft was then folded in order to prepare it for delivery. To accomplish this a stainless steel wire which was a couple of inches longer than the stent-graft was inserted through the lumen of the stent-graft. The stent-graft was flattened and the stainless steel wire positioned at one end of the stent-graft. A second stainless wire of about the same length was placed on the outer surface of the stent-graft adjacent to the first stainless steel wire. The wires were then mounted together into a fixture, tensioned and then rotated, thereby folding the stent-graft as shown in

FIGS. 15C & D

which will be discussed in more detail below. As the stent-graft rotates it is pressed into a “C” shaped elongated stainless steel clip in order to force it to roll upon itself. The folded stent-graft is then advanced along the wire out of the clip into a glass capture tube. A removable tether line, which is used to constrain the stent-graft in the rolled configuration for delivery, as will be discussed in more detail below, is applied to the stent-graft at this point by gradually advancing the stent-graft out of the capture tube and lacing the tether line through the stent-graft structure. After this step is completed, the stent-graft is pulled off of the first wire and transferred onto the distal end of the catheter shaft or tubing for delivery.




Prior to folding, the stent-graft was cooled to about −30° C. so that the nitinol was fully martensitic and, thus, malleable. This is done to allow the stent-graft to be more easily folded. Cooling is accomplished by spray soaking the graft with chilled gas such as tetrafluroethane. Micro-Dust™ dry circuit duster manufactured by MicroCave Corporation (Conn) provides suitable results. The spray canister was held upside down to discharge the fluid as a liquid onto the stent-graft.




Deployment of the Stent-Graft




The stent-graft may be delivered percutaneously, typically through the vasculature, after having been folded to a reduced diameter. Once reaching the intended delivery site, it is expanded to form a lining on the vessel wall.




When a stent-graft having torsion members, as described above, is folded, crushed, or otherwise collapsed, mechanical energy is stored in torsion in those members. In this loaded state, the torsion members have a torque exerted by the torsion members as folded down to a reduced diameter must be restrained from springing open. The stent-member preferably has at least one torsion member per fold. The stent-graft is folded along its longitudinal axis and restrained from springing open. The stent-graft is then deployed by removing the restraining mechanism, thus allowing the torsion members to spring open against the vessel wall. The stent grafts of this invention are generally self-opening once deployed. If desired, an inflatable balloon catheter or similar means to ensure full opening of the stent-graft may be used under certain circumstances.




The attending physician will select an appropriately sized stent-graft. Typically, the stent-graft will be selected to have an expanded diameter of up to about: 10% greater than the diameter of the lumen at the deployment site.





FIG. 15A

diagrammatically illustrates a folding sequence for folding a stent-graft constructed according to the present invention. The stent-graft, generally designated with reference numeral


200


is positioned about a guidewire


232


and folded into a loose C-shaped configuration.

FIG. 15B

shows a diagrammatic perspective view of the resulting folded stent-graft.

FIGS. 15C & E

show further folding sequences.

FIGS. 15D & F

show diagrammatic perspective views of the resulting folded stent-grafts showing the rolled and triple lobed configurations, respectively. The rolled configuration is preferred.





FIGS. 16A-16C

diagrammatically illustrate deployment procedures for the present invention.

FIG. 16A

shows an example target site having a narrowed vessel lumen. A guidewire


208


having a guide tip has been directed to the site using known techniques. The stent-graft


210


is mounted on guidewire tubing


212


inside outer sliding sheath


214


after having been folded in the manner discussed above. The outer sliding sheath


214


binds the compressed stent-graft


210


in place until released.





FIG. 16B

shows placement of the stent-graft


120


at the selected site by sliding the stent-graft over the guidewire all together with the guidewire tubing


212


and the outer sliding sheath


214


. The stent-graft is deployed by holding the guidewire tubing


212


in a stationary position while withdrawing the outer sliding sheath


214


.

FIG. 16B

shows the stent-graft partially deployed, while

FIG. 16C

shows the stent-graft fully deployed after the guidewire tubing and the outer sliding sheath have been fully retracted.





FIGS. 17A-C

,


18


A-C, and


19


A-C show deployment variations for deploying a stent-graft constructed according to the present invention. These methods involve the use of a control line or tether line which maintains the stent or stent-graft in a folded configuration until release.




Referring to

FIGS. 17A & B

, diagrammatically represented stent-graft


302


is shown folded about guidewire


304


so that, when deployed, the guidewire


304


is within stent-graft


302


. A tether wire


306


is passed through loops


308


which preferably are formed by pulling the linking member discussed above away from the stent structure. When tether wire


306


is removed by sliding it axially along the stent-graft and out of loops


308


, the stent-graft unfolds into a generally cylindrical shape. (FIG.


17


C). Referring to,

FIGS. 18A & B

stent-graft


302


is shown in a rolled pre-deployment configuration. In this case, guidewire


304


is inside the stent. When expanded by removal of tether wire


306


, the stent-graft assumes the form shown in FIG.


18


C.





FIGS. 19A-C

diagrammatically show additional procedures for deploying a stent-graft of the present invention using a percutaneous catheter assembly


314


. Referring to

FIG. 19A

catheter assembly


314


has been inserted to a selected site within a body lumen. Stent-graft


312


is folded about guidewire


319


and guidewire tube


318


held axially in place prior to deployment by distal barrier


320


and proximal barrier


322


. The distal and proximal barriers typically are affixed to the guidewire tube


318


. Tether wire


306


is extends through loops


308


proximally through the catheter assembly's


314


outer jacket


324


through to outside the body.

FIG. 19B

shows partial removal of tether wire


306


from loops


308


to partially expand the stent-graft


312


onto the selected site.

FIG. 19C

shows complete removal of the tether wire, the loops and retraction of the catheter assembly


314


from the interior of the stent-graft which is fully expanded.





FIG. 20

shows a close-up of a stent fold line having the familiar herringbone pattern of the preferred “sack knot” used to close the fold in the stent. This knot is the one used to hold, e.g., burlap sacks of feed grain closed prior to use and yet allow ease of opening when the sack is to be opened. In this variation, the slip line has a fixed end


320


and a release end


322


. Loops of the slip line pass through the eyelets


324


on the side of the stent fold associated with the fixed end


320


and are held in place by eyelets


326


on the side of the stent fold associated with the release end


322


. The fixed end


320


is not typically tied to the stent so to allow removal of the slip line after deployment. The eyelets


324


and


326


are desirable but optional. The eyelets


324


and


326


may be wire or polymeric thread or the like tied to the stent structure at the edge of the stent fold. If so desired, the loops may be dispensed with and the slip line woven directly into the stent structure. The self-expanding stent may be deployed by pulling axially on release end


322


as shown by the arrow in the drawing.





FIG. 21

is a diagrammatic perspective view of a folded stent-graft using the knot shown in FIG.


20


.

FIG. 21

shows the use of a single stent fold similar in configuration to those described above. As was shown in

FIG. 20

, the fixed end portion


320


of the slip line is associated with a row of eyelets


324


which preferably are formed by pulling local portions of linking member


20


away from the fold line, threading the slip line therethrough and then releasing the respective portion of the linking member. Alternatively, the eyelets may be tied or otherwise fixed to the stent. The release end


322


is associated with the other row of eyelets


326


.




Although stent-graft deployment is described using a catheter for percutaneous delivery, it should be understood that other deployment techniques may be used. The folded stent-graft may also be deployed through artificial or natural body openings with a sheath or endoscopic delivery device, for example, and perhaps, without a guidewire. Similarly, the stent-graft may be delivered manually during a surgical procedure.




The stent-graft of the present invention may be used, for example, to reinforce vascular irregularities and provide a smooth nonthrombogenic interior vascular surface for diseased areas in blood vessels, or to increase blood flow past a diseased area of a vessel by mechanically improving the interior surface of the vessel. The inventive stent-graft is especially suitable for use within smaller vessels between 2 mm and 6 mm in diameter but is equally suitable for significantly larger vessels. The inventive stent-graft may be self-expanded so that it may be percutaneously delivered in a folded state on an endovascular catheter or via surgical or other techniques and then expanded. The stent-graft construction described above also provides a variable length stent-graft. This is especially advantageous during implantation procedures.




Currently, it is difficult for a physician to accurately determine anatomical distances due to vessel tortuosity in different planes which often occurs in aorta/iliac aneurysmal disease. Also, it is important for the physician to accurately measure distances when placing an endovascular stent-graft so the entire aneurysmal length is covered, yet important vessel branches are not occluded. The stent-graft design of the present invention allows the physician to adjust its length during deployment allowing more accurate placement of the device.




The following example illustrates the steps involved in placing a variable-length stent-graft into a patient's anatomy. In this example, stent-graft is a single tubular design, placed into the thoracic aorta


70


, and will be located between the renal arteries and the T-7 artery. The direction of deployment will be from renals ‘upstream’to the T-7 artery. The device will be supplied in its longest state with shortening capability during deployment (the inverse where a copressed stent-graft is deployed also is possible).




The physician estimates the length required, and chooses a device which is at least as long, and usually slightly longer than the estimated length.




The stent-graft is inserted through an introducer as is conventional in the art. It is advanced until its distal ends


2




a


is located as desired near the renal arteries (


72


) (FIG.


22


). At this point, the proximal end of the stent-graft would be located at or past the T-7 artery (


74


).




The stent-graft deployment is initiated slowly, distal to proximal (‘downstream to upstream’) (

FIG. 23

) while watching the proximal end location on fluoroscopy.




As needed, the delivery catheter


76


, which is of conventional construction, would be pulled toward the operator, shortening the stent-graft to keep the proximal end in the correct location. This shortening can occur as long as the portion of the stent-graft being compressed is within the aneurysm


78


.




Once the proximal end is correctly located (FIG.


24


), the stent graft is fully deployed, and the delivery catheter is removed (FIG.


25


).




Throughout this application, various publications, patents and patent applications are referred by an identifying citation. The disclosures of these publications, patents and published patent applications are hereby incorporated by referenced into this application.




The above is a detailed description of a particular embodiment of the invention. The full scope of the invention is set out in the claims that follow and their equivalents. Accordingly, the claims and specification should not be construed to unduly narrow the full scope of protection to which the invention is entitled.



Claims
  • 1. A process for making a stent graft comprising:(a) placing a graft member around a mandrel; (b) positioning an undulating stent member having an inner surface and an outer surface around said graft member; and (c securing said stent member to said graft member with a ribbon having multiple spaced apart strips, which ribbon is adhered to at least one of the inner and outer surfaces of said stent member, to form a stent-graft assembly.
  • 2. The process according to claim 1 further comprising the step of:(a1) prior to step (a), placing a cushioning layer around the mandrel.
  • 3. The process according to claim 1, wherein said securing step comprises helically wrapping the ribbon around the stent member whereby adjacent turns of the helically wrapper ribbon are spaced from one another and form said spaced apart strips.
  • 4. The process according to claim 2, wherein said securing step comprises helically wrapping the ribbon around the stent whereby adjacent turns of the helically wrapper ribbon are spaced from one another.
  • 5. The process according to claim 2 wherein the ribbon is bonded to an outer surface of the graft member.
  • 6. The process according to claim 1 further comprising the step of:(d) placing a sheath around the assembly of step (c) to form a compressed assembly.
  • 7. The process according to claim 6 further comprising the step of:(e) heating the assembly of step (d) to adhere the ribbon to the graft member.
  • 8. The process according to claim 4 further comprising:(d) placing a tubular sheath having a longitudinal slit around the assembly of step (c); and (e) helically wrapping a film around the sheath to compress the assembly.
  • 9. The processing according to claim 6 wherein the sheath includes a helical wrapping of PTFE film.
  • 10. The stent-graft of claim 6 wherein one side of said ribbon has a coating of fluorinated ethylene propylene polymer.
CONTINUING DATA

This application is a divisional application of U.S. application Ser. No. 08/896,805, filed Jul. 18, 1997, now U.S. Pat. No. 6,042,605, which is a continuation-in-part of Ser. No. 08/572,548, filed Dec. 14, 1995, now abandoned, the entirety of which is incorporated herein by reference.

US Referenced Citations (338)
Number Name Date Kind
2638093 Kulick May 1953 A
3029819 Starks Apr 1962 A
3096560 Liebig Jul 1963 A
3142067 Liebig Jul 1964 A
3152618 Rothermel et al. Oct 1964 A
3174851 Buehler et al. Mar 1965 A
3351463 Rozner et al. Nov 1967 A
3479670 Medell Nov 1969 A
3514791 Sparks Jun 1970 A
3562820 Braun Feb 1971 A
3625198 Sparks Dec 1971 A
3657744 Ersek Apr 1972 A
3710777 Sparks Jan 1973 A
3753700 Harrison et al. Aug 1973 A
3774596 Cook Nov 1973 A
3805301 Liebig Apr 1974 A
3866247 Sparks Feb 1975 A
3866609 Sparks Feb 1975 A
3868956 Alfidi et al. Mar 1975 A
3927422 Sawyer Dec 1975 A
3938524 Sparks et al. Feb 1976 A
3949073 Daniels et al. Apr 1976 A
3953566 Gore Apr 1976 A
3974526 Dardik et al. Aug 1976 A
3993045 Ion Nov 1976 A
4011861 Enger Mar 1977 A
4047252 Liebig et al. Sep 1977 A
4130904 Whalen Dec 1978 A
4140126 Choudhury Feb 1979 A
4164045 Bokros et al. Aug 1979 A
4187390 Gore Feb 1980 A
4300244 Bokros Nov 1981 A
4306318 Mano et al. Dec 1981 A
4319363 Ketharanathan Mar 1982 A
4355426 MacGregor Oct 1982 A
4411655 Schreck Oct 1983 A
4424208 Wallace et al. Jan 1984 A
4425908 Simon Jan 1984 A
4488911 Luck et al. Dec 1984 A
4494531 Gianturco Jan 1985 A
4502159 Woodroff et al. Mar 1985 A
4503569 Dotter Mar 1985 A
4512338 Balko et al. Apr 1985 A
4517687 Liebig et al. May 1985 A
4530113 Matterson Jul 1985 A
4546500 Bell Oct 1985 A
4553545 Maass et al. Nov 1985 A
4557764 Chu Dec 1985 A
4562596 Kornberg Jan 1986 A
4580568 Gianturco Apr 1986 A
4582640 Smestad et al. Apr 1986 A
4592754 Gupte et al. Jun 1986 A
4604762 Robinson Aug 1986 A
4617932 Kornberg Oct 1986 A
4629458 Pinchuk Dec 1986 A
4641653 Rockey Feb 1987 A
4642117 Nguyen et al. Feb 1987 A
4647416 Seiler, Jr. et al. Mar 1987 A
4649922 Wiktor Mar 1987 A
4655771 Wallsten Apr 1987 A
4665906 Jervis May 1987 A
4689399 Chu Aug 1987 A
4728328 Hughes et al. Mar 1988 A
4733665 Palmaz Mar 1988 A
4738666 Fuqua Apr 1988 A
4739762 Palmaz Apr 1988 A
4740207 Kreamer Apr 1988 A
4760849 Kropf Aug 1988 A
4776337 Palmaz Oct 1988 A
4787899 Lazarus Nov 1988 A
4790313 Borrelly Dec 1988 A
4795458 Regan Jan 1989 A
4798606 Pinchuk Jan 1989 A
4800882 Gianturco Jan 1989 A
4816028 Kapadia et al. Mar 1989 A
4816339 Tu et al. Mar 1989 A
4820298 Leveen et al. Apr 1989 A
4830003 Wolff et al. May 1989 A
4842575 Hoffman, Jr. et al. Jun 1989 A
4856516 Hillstead Aug 1989 A
4877025 Hanson Oct 1989 A
4878906 Lindemann et al. Nov 1989 A
4886062 Wiktor Dec 1989 A
4886500 Lazarus Dec 1989 A
4892539 Koch Jan 1990 A
4913141 Hillstead Apr 1990 A
4921479 Grayzel May 1990 A
4941870 Okada et al. Jul 1990 A
4950227 Savin et al. Aug 1990 A
4955899 Corna et al. Sep 1990 A
4957504 Chardack Sep 1990 A
4957508 Kaneko et al. Sep 1990 A
4969458 Wiktor Nov 1990 A
4990151 Wallsten Feb 1991 A
4990155 Wilkoff Feb 1991 A
4994071 MacGregor Feb 1991 A
5007926 Derbyshire Apr 1991 A
5015253 MacGregor May 1991 A
5019085 Hillstead May 1991 A
5019090 Pinchuk May 1991 A
5035706 Gianturco et al. Jul 1991 A
5037377 Alonso Aug 1991 A
5037392 Hillstead Aug 1991 A
5037427 Harada et al. Aug 1991 A
5041126 Gianturco Aug 1991 A
5042161 Hodge Aug 1991 A
5064435 Porter Nov 1991 A
5066298 Hess Nov 1991 A
5067957 Jervis Nov 1991 A
5078726 Kreamer Jan 1992 A
5092877 Pinchuk Mar 1992 A
5100429 Sinofsky et al. Mar 1992 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5108424 Hoffman, Jr. et al. Apr 1992 A
5122154 Rhodes Jun 1992 A
5123917 Lee Jun 1992 A
5127919 Ibrahim et al. Jul 1992 A
5133732 Wiktor Jul 1992 A
5139480 Hickle et al. Aug 1992 A
5147370 McNamara et al. Sep 1992 A
5151105 Kwan-Gett Sep 1992 A
5156619 Ehrenfeld Oct 1992 A
5161547 Tower Nov 1992 A
5162430 Rhee et al. Nov 1992 A
5163958 Pinchuk Nov 1992 A
5171262 MacGregor Dec 1992 A
5178630 Schmitt Jan 1993 A
5192289 Jessen Mar 1993 A
5192307 Wall Mar 1993 A
5195984 Schatz Mar 1993 A
5197977 Hoffman, Jr. et al. Mar 1993 A
5197978 Hess Mar 1993 A
5201757 Heyn Apr 1993 A
5209735 Lazarus May 1993 A
5211658 Clouse May 1993 A
5213580 Slepian et al. May 1993 A
5217483 Tower Jun 1993 A
5221261 Termin et al. Jun 1993 A
5226913 Pinchuk Jul 1993 A
5232446 Arney Aug 1993 A
5236447 Kubo et al. Aug 1993 A
5242451 Harada et al. Sep 1993 A
5246452 Sinnott Sep 1993 A
5258042 Mehta Nov 1993 A
5264276 McGregor et al. Nov 1993 A
5271410 Wolzinger et al. Dec 1993 A
5276276 Gunn Jan 1994 A
5282824 Gianturco Feb 1994 A
5282846 Schmitt Feb 1994 A
5282847 Trescony et al. Feb 1994 A
5282848 Schmitt Feb 1994 A
5290305 Inoue Mar 1994 A
5306261 Alliger et al. Apr 1994 A
5306294 Winston et al. Apr 1994 A
5314472 Fontaine May 1994 A
5324304 Rasmussen Jun 1994 A
5324323 Bui Jun 1994 A
5330528 Lazim Jul 1994 A
5336254 Brennen et al. Aug 1994 A
5342347 Kaplan Aug 1994 A
5342387 Summers Aug 1994 A
5344426 Lau et al. Sep 1994 A
5348537 Wiesner et al. Sep 1994 A
5354308 Simon et al. Oct 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5356423 Tihon et al. Oct 1994 A
5360443 Barone et al. Nov 1994 A
5366472 Hillstead Nov 1994 A
5366473 Winston et al. Nov 1994 A
5366504 Andersen et al. Nov 1994 A
5370691 Samson Dec 1994 A
5372600 Beyar Dec 1994 A
5382261 Palmaz Jan 1995 A
5383928 Scott et al. Jan 1995 A
5385580 Schmitt Jan 1995 A
5387235 Chuter Feb 1995 A
5405377 Cragg Apr 1995 A
5405378 Strecker Apr 1995 A
5413598 Moreland May 1995 A
5421955 Lau et al. Jun 1995 A
5423849 Engelson et al. Jun 1995 A
5425710 Kahir et al. Jun 1995 A
5425739 Jessen Jun 1995 A
5443500 Sigwart Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5453084 Moses Sep 1995 A
5456713 Chuter Oct 1995 A
5456721 Legrand Oct 1995 A
5458605 Klemm Oct 1995 A
5458615 Klemm et al. Oct 1995 A
5464449 Ryan et al. Nov 1995 A
5476506 Lunn Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5484444 Braudschweiler Jan 1996 A
5487858 Schmitt Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5496364 Schmitt Mar 1996 A
5496365 Sgro Mar 1996 A
5499994 Tihon et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5507769 Marin et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5509902 Raulerson Apr 1996 A
5509931 Schmitt Apr 1996 A
5514154 Lau et al. May 1996 A
5522822 Phelps et al. Jun 1996 A
5522880 Barone et al. Jun 1996 A
5522881 Lentz Jun 1996 A
5522961 Leonhardt Jun 1996 A
5540701 Sharkey et al. Jul 1996 A
5540712 Kleshinski et al. Jul 1996 A
5545210 Hess et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5549635 Solar Aug 1996 A
5549663 Cottone, Jr. Aug 1996 A
5554180 Turk Sep 1996 A
5554181 Das Sep 1996 A
5554182 Dinh et al. Sep 1996 A
5556413 Lam Sep 1996 A
5562724 Vorwerk et al. Oct 1996 A
5562726 Chuter Oct 1996 A
5562727 Turk et al. Oct 1996 A
5571166 Dinh et al. Nov 1996 A
5571169 Plaia et al. Nov 1996 A
5571172 Chin Nov 1996 A
5571173 Parodi Nov 1996 A
5571176 Taheri Nov 1996 A
5575815 Slepian et al. Nov 1996 A
5575816 Rudnick et al. Nov 1996 A
5575817 Martin Nov 1996 A
5578071 Parodi Nov 1996 A
5591197 Orth et al. Jan 1997 A
5591198 Boyle et al. Jan 1997 A
5591228 Edoga Jan 1997 A
5591229 Parodi Jan 1997 A
5599305 Hermann et al. Feb 1997 A
5607442 Fischell et al. Mar 1997 A
5607444 Lam Mar 1997 A
5607445 Summers Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5620763 House et al. Apr 1997 A
5622188 Plaia et al. Apr 1997 A
5626561 Butler et al. May 1997 A
5628783 Quiachon et al. May 1997 A
5628784 Strecker May 1997 A
5628788 Pinchuk May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5637113 Tartaglia et al. Jun 1997 A
5639278 Dereueme et al. Jun 1997 A
5643208 Parodi Jul 1997 A
5647380 Campell et al. Jul 1997 A
5649978 Samson Jul 1997 A
5653743 Martin Aug 1997 A
5653748 Strecker Aug 1997 A
5662614 Edoga Sep 1997 A
5662675 Stockert et al. Sep 1997 A
5662701 Plaia et al. Sep 1997 A
5662713 Andersen et al. Sep 1997 A
5665117 Rhodes Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5669924 Shaknovich Sep 1997 A
5669930 Igarashi Sep 1997 A
5674276 Anderson et al. Oct 1997 A
5676671 Inoue Oct 1997 A
5676696 Marcade Oct 1997 A
5676697 McDonald Oct 1997 A
5681346 Orth et al. Oct 1997 A
5683449 Marcade Nov 1997 A
5683450 Goicoechea et al. Nov 1997 A
5683451 Lenker et al. Nov 1997 A
5683452 Barone et al. Nov 1997 A
5693084 Chuter Dec 1997 A
5693086 Goicoechea et al. Dec 1997 A
5693087 Parodi Dec 1997 A
5693088 Lazarus Dec 1997 A
5695517 Marin et al. Dec 1997 A
5697970 Schmitt et al. Dec 1997 A
5700285 Myers et al. Dec 1997 A
5700286 Taraglia Dec 1997 A
5709657 Zimmon Jan 1998 A
5713917 Leonhardt et al. Feb 1998 A
5716365 Goicoechea et al. Feb 1998 A
5718724 Goicoechea et al. Feb 1998 A
5718973 Lewis et al. Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5723003 Winston et al. Mar 1998 A
5723004 Dereume et al. Mar 1998 A
5728131 Frantzen et al. Mar 1998 A
5728150 McDonald et al. Mar 1998 A
5730698 Fischell et al. Mar 1998 A
5732572 Litton Mar 1998 A
5741274 Lenker et al. Apr 1998 A
5741325 Chaikof et al. Apr 1998 A
5749825 Fischell et al. May 1998 A
5749921 Lenker et al. May 1998 A
5755769 Richard et al. May 1998 A
5769882 Forgarty et al. Jun 1998 A
5779732 Amundson Jul 1998 A
5782904 White et al. Jul 1998 A
5800521 Orth Sep 1998 A
5800522 Campbell et al. Sep 1998 A
5800524 Borghi Sep 1998 A
5810870 Myers et al. Sep 1998 A
5824041 Lenker et al. Oct 1998 A
5843069 Butler et al. Dec 1998 A
5843171 Campbell et al. Dec 1998 A
5865723 Love Feb 1999 A
5868704 Campbell et al. Feb 1999 A
5873906 Lau et al. Feb 1999 A
5876432 Lau et al. Mar 1999 A
5888243 Silvestrini Mar 1999 A
5919225 Lau et al. Jul 1999 A
5925061 Ogi et al. Jul 1999 A
5925075 Myers et al. Jul 1999 A
5961546 Robinson et al. Oct 1999 A
5972441 Campbell et al. Oct 1999 A
5976650 Campbell et al. Nov 1999 A
5993489 Lewis et al. Nov 1999 A
6001123 Lau Dec 1999 A
6015429 Lau et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6017362 Lau Jan 2000 A
6019787 Richard et al. Jan 2000 A
6025044 Campbell et al. Feb 2000 A
6027779 Campbell et al. Feb 2000 A
6027811 Campbell et al. Feb 2000 A
6048484 House et al. Apr 2000 A
6086604 Fischell et al. Jul 2000 A
6120477 Campbell et al. Sep 2000 A
6019788 Butters et al. Oct 2000 A
6139572 Campbell et al. Oct 2000 A
6159565 Campbell et al. Dec 2000 A
6165210 Lau et al. Dec 2000 A
6193745 Fogarty et al. Feb 2001 B1
6203568 Lombardi et al. Mar 2001 B1
Foreign Referenced Citations (70)
Number Date Country
4248589 Apr 1990 AU
3474293 Jan 1993 AU
2026604 Apr 1991 CA
2079417 Apr 1993 CA
37 24 514 Feb 1989 DE
39 18736 Dec 1990 DE
39 18 736 Dec 1990 DE
41 37 857 May 1992 DE
197-17-823 Nov 1997 DE
0 382 014 Aug 1990 EP
0 408 245 Jan 1991 EP
0 418 677 Mar 1991 EP
0 423 916 Apr 1991 EP
0 435 518 Jul 1991 EP
0 464 755 Jan 1992 EP
0 472 731 Mar 1992 EP
0 540 290 May 1993 EP
0 551 179 Jul 1993 EP
0 556 850 Aug 1993 EP
0 565 251 Oct 1993 EP
0 667 131 Jan 1995 EP
0 689 806 May 1995 EP
0 686 379 Dec 1995 EP
0 696 447 Feb 1996 EP
0 701 800 Mar 1996 EP
0 705 577 Apr 1996 EP
0 716 834 Jun 1996 EP
0 747 020 Dec 1996 EP
2 678 508 Aug 1993 FR
1 506 432 Apr 1978 GB
1 567 122 May 1980 GB
1 355 373 Jun 1994 GB
02-174859 Jul 1990 JP
06-007454 Jan 1994 JP
06-181993 Jul 1994 JP
7-500272 Jan 1995 JP
07-024688 Mar 1995 JP
8-509899 Oct 1996 JP
1635980 Dec 1988 SU
WO 8806026 Aug 1988 WO
WO 9004982 May 1990 WO
WO 9203107 Mar 1992 WO
WO 9204097 Mar 1992 WO
WO 9206734 Apr 1992 WO
WO 9209246 Jun 1992 WO
WO 9313825 Jul 1993 WO
WO 9317636 Sep 1993 WO
WO 9319803 Oct 1993 WO
WO9319804 Oct 1993 WO
WO 9322984 Nov 1993 WO
WO 9322989 Nov 1993 WO
WO 9400179 Jan 1994 WO
WO 9401483 Jan 1994 WO
WO 9404097 Mar 1994 WO
WO 9412136 Jun 1994 WO
WO 9415549 Jul 1994 WO
WO 9501466 Feb 1995 WO
WO 9505131 Feb 1995 WO
WO 9505132 Feb 1995 WO
WO 9509586 Apr 1995 WO
WO 9521592 Aug 1995 WO
WO 9526695 Oct 1995 WO
WO 9610967 Apr 1996 WO
WO 9618360 Jun 1996 WO
WO 9618361 Jun 1996 WO
WO 9624306 Aug 1996 WO
WO 9721402 Jun 1997 WO
WO 9721403 Jun 1997 WO
WO 9721641 Jun 1997 WO
WO 9830173 Jul 1998 WO
Non-Patent Literature Citations (26)
Entry
Cragg, et al: Percutaneous Femoropopliteal Graft Placement; J. Vascular and Interventional Radiology; pp. 455-462; Jul.-Aug. 1993; vol. 4, No. 4.
Cragg, et al; Nitinol Intravascular Stent: Results of Preclinical Evaluation; Radiology; pp. 775-778; Dec. 1993; vol. 189, No. 3.
Cragg, “Percutaneous Femoropopliteal Graft Placement” Radiology (1993) 187 (3): 643-648.
Hagen et al, “Self-Expandable Macroporous Nitinol Stents for Transfemoral Exclusion of Aortic Aneurysms in Dogs: Preliminary Results” Cardiovascular Intervention Radiology (1993) 16:339-342.
Laborde et al., “Intraluminal Bypass of Abdominal Aortic Aneurysm: Feasibility Study”; Radiology 1992, 184: 185-190.
Product Brochure for Cook-Z Stents, Gianturco-Rösch Biliary Design, Cook®, a Cook Groups Company, P.O. box 489, Bloomington, IN, 47402, U.S.A., 4 pgs. total, (1989).
Neuwirth, MinTec™ Minimally Invasive Technologies Product Brochure for the Craggstent and Cragg EndoPro System 1, 4 pgs.
Blum, U. et al.; “Dacron Endografts for Infrarenal Abdominal Aortic Aneurysms: 2 Year Follow-up”; Fifth international and Interdisciplinary Symposium on Endoluminal Stents and Grafts (Oct. 10-13, 1996) Washington, D.C., 2 pages total.
Chuter et al.; “Bifurcated stent-grafts for AAA: 3 year follow-up”; Abstracts from the Seventh International Course on Peripheral Vascular Intervention; J. Endovas. Surg. (1996) 3:453.
Chuter et al.; “Bifurcated stent-grafts for AAA: 3 year follow-up”, Fifth International and Interdisciplinary Symposium on Endoluminal Stents and Grafts (Oct. 10-13, 1996) Washington, D.C., 2 pages total.
Dereume, JP et al.; “Endoluminal Treatment of Abdominal Aortic Aneurysm with the Corvita Endovascular Graft, Results of a Single-Center, Prospective Feasibility Study of 90 Patients”; Abstracts from the Seventh International Course on Peripheral Vascular Intervention J. Endovasc. Surg. (1996) 3:460-461.
Katzen et al.; “Initial experience performing conbined surgical/intervention procedures in the interventional suite” Abstracts from the Seventh International Course on Peripheral Vascular Intervention J. Endovasc. Surg. (1996) 3:467.
Moore et al., “Transfermoral endovascular repair of abdominal aortic aneurysm: Result of the North American EVT phase 1 trial” J. Vasc. Surg. (1996) 23:543-552.
Parodi et al., “long-term follow-up of AAA endoluminal repair” Abstracts from the Seventh International Course on Peripheral Vascular Intervention. J. Endovasc. Surg. (1996) 3:335.
White et al., “Endoleak following endoluminal repair of AAA: Diagnosis, significance, and amanagement” Abstracts from the Seventh International Course on Peripheral Vascular Intervention J. Endovasc. Surg. (1996) 3:339-340.
Wilson et al.; “A self expanding bifurcated endovascular graft for Abdominal Aortic Aneurysm Repair. An Initial Study in a Canine Model” ASAIO Journal 42(5): 386-393 (1996).
World Medical News, World Medical manufacturing Corporation, 13794 NW 4th Street, Bldgs. 210 & 211, Sunrise, Florida, 33325 U.S.A., vol. 5, Issue 3 (Jul. 1996) 3 pages total.
U.S. application No. 08/871,427, Lau, et al., filed Jun. 9, 1997 and pending claims as of Apr. 16, 2001.
U.S. application No. 09/207,944, Vonesh et al., filed Dec. 9, 1998 and response dated Aug. 21, 2000.
U.S. application No. 09/235,214, Brauker et al., filed Jan. 22, 1999.
U.S. application No. 09/235,458, Vonesh et al., filed Jan. 22, 1999 and response dated Sep. 28, 2000.
U.S. application No. 09/306,522, Myers, filed May 6, 1999.
U.S. application No. 09/408,866, Brenton et al., filed Sep. 30, 1999 and response dated Jan. 10, 2001.
U.S. application No. 09/488,229, Cully et al., filed Jan. 20, 2000.
U.S. application No. 09/489,604, Vonesh et al., filed Jan. 20, 2000.
U.S. application No. 09/510,937, Goffena et al., filed Feb. 22, 2000 and response dated Oct. 5, 2000.
Continuation in Parts (1)
Number Date Country
Parent 08/572548 Dec 1995 US
Child 08/896805 US